Cargando…
Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)
Although nivolumab is known to cause immune-related interstitial lung diseases (ILD), the detailed characteristics of ILD are still not fully understood. A 68-year-old man was treated with nivolumab because of unresectable sinonasal melanoma, he achieved a complete response soon after the initiation...
Autores principales: | Ishiwata, Tsukasa, Ebata, Takahiro, Iwasawa, Shunichiro, Matsushima, Jun, Ota, Satoshi, Nakatani, Yukio, Tsushima, Kenji, Tada, Yuji, Tatsumi, Koichiro, Takiguchi, Yuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635305/ https://www.ncbi.nlm.nih.gov/pubmed/28794361 http://dx.doi.org/10.2169/internalmedicine.8271-16 |
Ejemplares similares
-
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation
por: KURIMOTO, RYOTA, et al.
Publicado: (2016) -
Potential Activity of Amrubicin as a Salvage Therapy for Merkel Cell Carcinoma
por: Sakaida, Emiko, et al.
Publicado: (2017) -
Identification of factors during bronchoscopy that affect patient reluctance to undergo repeat examination: Questionnaire analysis after initial bronchoscopy
por: Fujimoto, Kazushi, et al.
Publicado: (2018) -
Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study
por: Abe, Mitsuhiro, et al.
Publicado: (2015) -
Clinical Characteristics and Risk Factors of Lung Injury Induced by Nab-Paclitaxel
por: Yoshioka, Keiichiro, et al.
Publicado: (2022)